Needham & Company Downgrades NuVasive (NUVA) to Underperform

Needham & Company downgraded NuVasive (NASDAQ: NUVA) from Hold to Underperform.

Analyst Mike matson says a resurgent MDT puts the company estimates at risk. The analyst comments "We expect NUVA's revenue growth to approach the mid-single digits and its EPS growth to approach the mid-teens and we think this warrants a ~25x P/E multiple putting its fair value at around ~$50/share."

For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.

Shares of NuVasive closed at $61.64 Friday.

You May Also Be Interested In

• Needham Starts Faeth Therapeutics (FTH) at Buy
• Nomura/Instinet Downgrades Pop Mart International Group Ltd (9992:HK) to Neutral
• Ferrovial SA (FER:SM) (FRRVF) Reiterated at Buy by UBS on Winning Bid For Tennessee Project